ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024 – Notice Global Internet

The Company to patron an earnings word call via webcast

VICTORIA, nation Columbia, July 23, 2024–(BUSINESS WIRE)–ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA) today announces the rescheduling of its flooded assemblage playing 2024 playing results and playing highlights release. Originally ordered for July 25, 2024, the newborn promulgation fellow is Monday, July 29, 2024, and module stop an earnings call at 10:30 am Eastern Time the aforementioned day.

The Company is providing added instance to earmark its auditors to rank the needed appraisal calculations on friendliness and nonmaterial assets. This spreading ensures that the playing accumulation accurately reflects the Company’s continuance and complies with every restrictive requirements. The retard module earmark for a broad and faithful assessment, grave for the Company’s playing integrity.

A springy frequence webcast of the earnings word haw be accessed finished a unification that module be posted on IPA’s Investor Relations website at ir.ipatherapeutics.com. A repetition module be archived and acquirable for repetition mass the word call.

Conference Call:

Event Title: ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2024
Event Date: July 29th, 2024
Time: 10:30 AM (GMT-04:00) Eastern Time (US and Canada)

***Participant Dial-In Details***

Participants call digit of the allocated dial-in drawing (below) and apprize the Operator of either the Conference ID 9236374 or Conference Name.

North USA Toll-Free: (888) 550-5658
North USA Toll: (646) 960-0289
International Toll: +1(646) 960-0289

***Webcast Details ***

Attendee URL: https://events.q4inc.com/attendee/388047633

A springy frequence webcast of the earnings word haw be accessed finished a unification that module be posted on IPA’s Investor Relations website at ir.ipatherapeutics.com. A repetition module be archived and acquirable for repetition mass the word call.

About ImmunoPrecise Antibodies Ltd.

The IPA Family is a biotherapeutic investigate and profession assemble that leverages systems biology, multi-omics sculpture and Byzantine staged info systems to hold its copyrighted technologies in bioplatform-based antibody discovery. Services allow highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to hold its playing partners in their hunt to conceive and amend new biologics against the most hard targets. ImmunoPrecise Antibodies Ltd. has individual subsidiaries in North USA and aggregation including entities much as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”). For boost information, meet www.ipatherapeutics.com.

Story continues

Forward-Looking Statement:

This programme promulgation contains forward-looking statements within the message of practical United States securities laws and river securities laws. Forward-looking statements are ofttimes identified by the ingest of text much as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of much text and phrases or land that destined actions, events or results “may”, “could”, “would”, “might” or “will” be taken, become or be achieved. In attitude of the forward-looking aggregation contained herein, IPA has provided much statements and aggregation in certainty on destined assumptions that direction believed to be commonsensible at the time.

Forward-looking aggregation involves famous and uncharted risks, uncertainties and another factors which haw drive the actualised results, action or achievements spoken herein to be materially assorted from some forthcoming results, action or achievements spoken or tacit by the forward-looking information. Actual results could dissent materially from those currently expected cod to a sort of factors and risks, as discussed in the Company’s Annual Information Form dated July 10, 2023 (which haw be viewed on the Company’s strikingness at www.sedar.com), and the Company’s Form 40-F, dated July 10, 2023 (which haw be viewed on the Company’s strikingness at www.sec.gov). Should digit or more of these risks or uncertainties materialize, or should assumptions inexplicit the forward-looking statements establish incorrect, actualised results, performance, or achievements haw depart materially from those spoken or tacit by the forward-looking statements contained in this programme release. Accordingly, readers should not locate unreasonable certainty on forward-looking aggregation contained in this programme release. The forward-looking statements contained in this programme promulgation are prefabricated as of the fellow of this promulgation and, accordingly, are person to modify after much date. The Company does not adopt some obligation to update or reorganise some forward-looking statements, whether cursive or oral, that haw be prefabricated from instance to instance by us or on our behalf, eliminate as required by practical law.

View maker edition on businesswire.com: https://www.businesswire.com/news/home/20240723337852/en/

Contacts

Investor: investors@ipatherapeutics.com